Keryx Biopharmaceuticals — FY2016 Earnings Presentation
20 slides from Keryx Biopharmaceuticals's earnings presentation, Mar 1, 2017
Slide 1: Fourth Quarter and Full Year 2016 Financial Results
Keryx Biopharmaceuticals, Inc. Fourth Quarter and Full Year 2016 Financial Results March 1, 2017 Building a Leading Renal Company Exhibit 99.2
Slide 2: Agenda - Fourth Quarter and Full Year 2016 Financial Results
Agenda - Fourth Quarter and Full Year 2016 Financial Results Topic Speaker Introduction Amy Sullivan, SVP, Corporate Affairs Business Highlights Greg Madison, President and CEO Financial Results Scott Holmes, SVP and CFO Near-term Opportunities and Outlook Greg Madison, President and CEO Question &
Slide 3: Forward-looking Statements
Forward-looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development of Auryxia, the submission of an sNDA to the FDA to expand the label of ferric citrate to include the treatment of IDA in adults with s
Slide 4: Building a Leading Renal Company
Building a Leading Renal Company Today Near Term Future One medicine, multiple indications Multi-product company focused on improving the lives of people with renal disease One medicine, one indication Auryxia is currently indicated for the control of serum phosphorus levels in CKD patients on dialy
Slide 5: Early positive momentum for Auryxia in dialysis
Early positive momentum for Auryxia in dialysis ~8,700 prescriptions for 4Q16, including ~4,500 prescriptions in December ~4,650 prescriptions in January 2017; 3.3% sequential month growth compared to overall market decline of 2.6% decline Well Positioned for Growth Commercial Progress Label Expansi
Slide 6: Financial Highlights
Financial Highlights Scott Holmes SVP and Chief Financial Officer
Slide 7: Fourth Quarter and Full Year 2016 Financial Highlights
Fourth Quarter and Full Year 2016 Financial Highlights ($ in millions) Q4 2016 (unaudited) Q4 2015 (unaudited) 2016 (audited) 2015 (audited) Auryxia Net U.S. Product Sales $ 8.2 $ 4.8 $ 27.2 $ 10.1 License Revenue $ 1.3 $ 1.0 $ 4.8 $ 3.6 Total Revenue $ 9.5 $ 5.8 $ 32.0 $ 13.7 Cost of Goods Sold* $
Slide 8: Near-term Opportunities and Outlook
Near-term Opportunities and Outlook Greg Madison President and Chief Executive Officer
Slide 9: Potential to Manage Two Complications of CKD Could Drive Market Leadership
Potential to Manage Two Complications of CKD Could Drive Market Leadership Phosphate Management Anemia Management Auryxia is currently indicated for the control of serum phosphorus levels in CKD patients on dialysis; Ferric citrate is being evaluated for use in non-dialysis dependent CKD patients as
Slide 10: Significant Opportunity Exists to Increase Number of People Treated with Auryxia
Significant Opportunity Exists to Increase Number of People Treated with Auryxia ~ $2.2B Market ~$2.8B Market Market sizes are based on Auryxia dollars; Dialysis market size based on 350,000 patients, 6 tablets/day, $5.04 WAC/tablet, and a 42% gross to net adjustment. IDA near-term potential market
Slide 11: Market Insights Show Auryxia's Brand Perception Remains Strong
Positive indicators from market insights*: Auryxia brand perception remain strong Auryxia utilization expectations at or above pre-interruption levels Strong momentum in early 2017: Majority of previously treated patients recaptured since returning to market Focus now on getting new patients on Aury
Slide 12: Building Momentum in Dialysis
Building Momentum in Dialysis Supply Interruption Prescriptions Filled Sources: IMS, Davita Rx, Fresenius Rx and Keryx data on file. Dec. ‘16 – Jan. ‘17: Auryxia: + 3.3% vs. Phosphate binder market: - 2.6%
Slide 13: Market Insights: Need Exists for Effective, Well Tolerated, Convenient IDA Treatment
Market Insights: Need Exists for Effective, Well Tolerated, Convenient IDA Treatment Goal: Position Auryxia as a new standard of care for the management of IDA in NDD-CKD Physician Perceptions of Current Treatment Options for IDA Oral Iron Widely available, inexpensive Nephrologists report low satis
Slide 14: Oral Iron Satisfaction is Low Compared to Other CKD Treatments
Oral Iron Satisfaction is Low Compared to Other CKD Treatments Speherix RealTime Dynamix June 2016 Overall, how satisfied are you with the performance of each drug class / product below. Please rate each on a scale of 1 to 10, where "1" is "Not at all satisfied" and "10" is "Extremely Satisfied“ (n=
Slide 15: Market Insights: Need Exists for Effective, Well Tolerated, Convenient IDA Treatment
Market Insights: Need Exists for Effective, Well Tolerated, Convenient IDA Treatment Goal: Position Auryxia as a new standard of care for the management of IDA in NDD-CKD Physician Perceptions of Current Treatment Options for IDA Oral Iron Widely available, inexpensive Nephrologists report low satis
Slide 16: Auryxia Strategic Priorities in IDA, NDD-CKD
Auryxia Strategic Priorities in IDA, NDD-CKD Establish a new oral iron-centric treatment paradigm for anemia in NDD-CKD Differentiate Auryxia from traditional oral irons Position Auryxia as a new standard of care for the management of IDA in NDD-CKD
Slide 17: IDA, NDD-CKD Indication Would Provide Significant Leverage
Current field based infrastructure Keryx phosphate binder nephrology targets account for ~80% of oral iron prescriptions in CKD Broad awareness and familiarity of Auryxia Established access and reimbursement Existing formulary coverage would provide access to majority of IDA, NDD/CKD patients Existi
Slide 18: Building a Leading Renal Company: Three Strategic Pathways
Building a Leading Renal Company: Three Strategic Pathways Drive and Support Keryx’s Planned Growth GROW INSPIRE Maximize Auryxia’s Potential Grow in US dialysis market Launch & grow in US IDA, NDD- CKD market Expand Portfolio Build Keryx by adding strategic assets to our portfolio Manage Growth & T
Slide 19: Key Takeaways
Key Takeaways Strong prescription momentum entering 2017 sNDA submitted in January 2017 seeking potential label expansion of Auryxia Large market opportunity for Auryxia in hyperphosphatemia and iron deficiency anemia IDA, NDD-CKD indication would leverage existing field based infrastructure, access
Slide 20: Keryx Biopharmaceuticals Fourth Quarter and Full Year 2016 Financial Results
Keryx Biopharmaceuticals Fourth Quarter and Full Year 2016 Financial Results March 1, 2017 Building a Leading Renal Company
Keryx Biopharmaceuticals — FY2016 Earnings Presentation on 6ix